Colorectal Cancer Clinical Trial
Official title:
CLOCC Trial (Chemotherapy + Local Ablation Versus Chemotherapy) Randomized Phase II Study Of Local Treatment Of Liver Metastases By Radiofrequency Combined With Chemotherapy Versus Chemotherapy Alone In Patients With Unresectable Colorectal Liver Metastases
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block tumor
growth in different ways. Some block the ability of tumor cells to grow and spread by
blocking blood flow. Others find tumor cells and help kill them or carry tumor-killing
substances to them. Radiofrequency ablation uses high-frequency electric current to kill
tumor cells. It is not yet known if chemotherapy is more effective with or without
radiofrequency ablation in treating liver metastases.
PURPOSE: This randomized phase II trial is studying combination chemotherapy, bevacizumab,
and radiofrequency ablation to see how well they work compared to combination chemotherapy
and bevacizumab alone in treating unresectable liver metastases in patients with colorectal
cancer.
OBJECTIVES:
Primary
- Compare the 30-month overall survival rate of patients with unresectable liver
metastases secondary to colorectal adenocarcinoma treated with chemotherapy and
bevacizumab with or without radiofrequency interstitial ablation.
Secondary
- Compare overall survival of patients treated with these regimens.
- Compare quality of life of patients treated with these regimens.
- Determine the health economics associated with this study.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified
according to treatment center, prior adjuvant chemotherapy for primary cancer (yes vs no),
prior chemotherapy for liver metastases (yes vs no), and route of randomization (before
surgery vs during surgery). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Within 4 weeks of randomization, patients undergo radiofrequency interstitial
ablation (RFA) with or without additional resection of resectable lesions. Within 8
weeks after RFA, patients receive chemotherapy and bevacizumab.
- Arm II: Within 4 weeks of randomization, patients receive chemotherapy and bevacizumab.
In both arms, treatment continues in the absence of disease progression or unacceptable
toxicity.
Patients in both arms receive one of the following chemotherapy and bevacizumab regimens to
be determined by participating center:
- Regimen A: Patients receive oxaliplatin IV over 2 hours on day 1 of weeks 1, 3, and 5
and leucovorin calcium IV over 2 hours followed by fluorouracil IV continuously over 24
hours on day 1 of weeks 1-6 and bevacizumab IV over 30-90 minutes on days 1 or 2, 15 or
16, and 29 or 30. Treatment repeats every 7 weeks for 4 courses.
- Regimen B: Patients receive oxaliplatin IV and leucovorin calcium IV over 2 hours on
day 1 followed by fluorouracil IV continuously over 46 hours and bevacizumab IV over
30-90 minutes on day 1 or 3. Treatment repeats every 15 days for 12 courses.
- Regimen C: Patients receive oxaliplatin IV over 2 hours on day 1 and leucovorin calcium
IV over 2 hours followed by fluorouracil IV continuously over 22 hours on days 1 and 2
and bevacizumab IV over 30-90 minutes on day 1 or 3. Treatment repeats every 15 days
for 12 courses.
Quality of life is assessed at baseline, within 1 week after completion of RFA (arm I only),
within 1 week before start of chemotherapy (arm I only), at weeks 6, 12, 18, and 24 during
chemotherapy, every 3 months for 2 years after treatment, and then every 6 months
thereafter.
After completion of study treatment, patients are followed every 3 months for 2½ years and
then every 6 months thereafter.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
PROJECTED ACCRUAL: A total of 152 patients (71 per treatment arm) will be accrued for this
study within 3 years.
;
Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |